ABC | Volume 111, Nº3, Setembro 2018

Diretrizes Diretriz Brasileira de Insuficiência Cardíaca Crônica e Aguda Arq Bras Cardiol. 2018; 111(3):436-539 651. TavazziL,MaggioniAP,LucciD,CacciatoreG,AnsaloneG,OlivaF,etal;Italian surveyonAcuteHeartFailureInvestigators.Nationwidesurveyonacuteheart failureincardiologywardservicesinItaly.EurHeartJ.2006;27(10):1207-15. 652. Tarvasmäki T, Lassus J, Varpula M, Sionis A, Sund R, Køber L, et al; CardShock study investigators. Current real-life use of vasopressors and inotropes in cardiogenic shock - adrenaline use is associated with excess organ injury and mortality. Crit Care. 2016;20(1):208. 653. Simões MM, Schwartzmann PV. Emprego de drogas inotrópicas e vasodilatadoras na insuficiência cardíaca aguda. In: Moreira MC, Montenegro ST, de Paola AM. (editores). Livro Texto da Sociedade Brasileira de Cardiologia. 2a. ed. São Paulo: Manole; 2015. p. 1195-212. 654. Magorien RD, Unverferth DV, Leier CV. Hydralazine therapy in chronic congestive heart failure. Sustained central and regional hemodynamic responses. Am J Med. 1984;77(2):267-74. 655. Leier CV, Desch CE, Magorien RD, TriffonDW, UnverferthDV, Boudoulas H, et al. Positive inotropic effects of hydralazine in human subjects: comparison with prazosin in the setting o congestive heart failure. Am J Cardiol. 1980;46(6):1039-44. 656. Binkley PF, Starling RC, Hammer DF, Leier CV. Usefulness of hydralazine to withdraw from dobutamine in severe congestive heart failure. Am J Cardiol. 1991;68(10):1103-6. 657. Shah MR, Hasselblad V, Stevenson LW, Binanay C, O'Connor CM, Sopko G, et al. Impact of the pulmonary artery catheter in critically ill patients: meta-analysis of randomized clinical trials. JAMA. 2005;294(13):1664-70. 658. Binanay C, Califf RM, Hasselblad V, O'Connor CM, Shah MR, Sopko G, et al; ESCAPE Investigators and ESCAPE Study Coordinators. Evaluation study of congestive heart failure and pulmonary artery catheterization effectiveness: the ESCAPE trial. JAMA. 2005;294(13):1625-33. 659. Sotomi Y, Sato N, Kajimoto K, Sakata Y, Mizuno M, Minami Y, et al; investigators of the Acute Decompensated Heart Failure Syndromes (ATTEND) Registry. Impact of pulmonary artery catheter on outcome in patients with acute heart failure syndromes with hypotension or receiving inotropes: from the ATTENDRegistry. Int J Cardiol. 2014;172(1):165-72. 660. Jondeau G, Neuder Y, Eicher JC, Jourdain P, Fauveau E, Galinier M, et al; B-CONVINCED Investigators. B-CONVINCED: Beta-blocker CONtinuation Vs. INterruption in patients with Congestive heart failure hospitalizED for a decompensation episode. Eur Heart J. 2009;30(18):2186-92. 661. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al; OPTIMIZE-HF Investigators and Coordinators. Influence of beta-blocker continuation or withdrawal on outcomes in patients hospitalized with heart failure: findings from the OPTIMIZE-HF program. J Am Coll Cardiol. 2008;52(3):190-9. 662. Orso F, Baldasseroni S, Fabbri G, Gonzini L, Lucci D, D'Ambrosi C, et al; Italian Survey on Acute Heart Failure Investigators. Role of beta-blockers in patients admitted for worsening heart failure in a real world setting: data from the Italian Survey on Acute Heart Failure. Eur J Heart Fail. 2009;11(1):77-84. 663. Dickstein K, Kjekshus J; OPTIMAAL Steering Committee of theOPTIMAAL Study Group. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal Trial inMyocardial Infarction with Angiotensin II Antagonist Losartan. Lancet. 2002;360(9335):752-60. 664. Beemath A, Stein PD, Skaf E, Al Sibae MR, Alesh I. Risk of venous thromboembolism in patients hospitalizedwith heart failure. Am J Cardiol. 2006;98(6):793-5. 665. Jois-Bilowich P, Michota F, Bartholomew JR, Glauser J, Diercks D, Weber J, et al; Adhere Scientific Advisory Committee and Investigators. Venous thromboembolismprophylaxis in hospitalized heart failure patients. J Card Fail. 2008;14(2):127-32. 666. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Prins MH, Tomkowski W, et al; ARTEMIS Investigators. Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 2006;332(7537):325-9. 667. ShivkumarK,JafriSM,GheorghiadeM.Antithrombotictherapyinatrialfibrillation: a reviewof randomized trials with special reference to the Stroke Prevention in AtrialFibrillationII(SPAFII)Trial.ProgCardiovascDis.1996;38(4):337-42. 668. Steg PG, Dabbous OH, Feldman LJ, Cohen-Solal A, Aumont MC, López- Sendón J, et al; Global Registry of Acute Coronary Events Investigators. Determinants and prognostic impact of heart failure complicating acute coronary syndromes: observations from the Global Registry of Acute Coronary Events (GRACE). Circulation. 2004;109(4):494-9. 669. Stone GW, Selker HP, Thiele H, Patel MR, Udelson JE, Ohman EM, et al. Relationship Between Infarct Size andOutcomes Following Primary PCI: Patient-Level Analysis From 10 Randomized Trials. J Am Coll Cardiol. 2016;67(14):1674-83. 670. Werdan K, Gielen S, Ebelt H, Hochman JS. Mechanical circulatory support in cardiogenic shock. Eur Heart J. 2014;35(3):156-67. 671. Lip GY, Heinzel FR, Gaita F, Juanatey JR, Le Heuzey JY, Potpara T, et al. European Heart Rhythm Association/Heart Failure Association joint consensus document on arrhythmias in heart failure, endorsed by the Heart Rhythm Society and the Asia Pacific Heart Rhythm Society. Eur J Heart Fail. 2015;17(9):848-74. 672. Tarasoutchi F, MonteraMW, Ramos AI, Sampaio RO, Rosa VE, Accorsi TA, et al. Atualização das Diretrizes Brasileiras de Valvopatias: abordagemdas lesões anatomicamente importantes. Arq Bras Cardiol. 2017;109(6 suppl 2):1-34. 673. Ristić AD, Imazio M, Adler Y, Anastasakis A, Badano LP, Brucato A, et al. Triage strategy for urgent management of cardiac tamponade: a position statement of the European Society of Cardiology Working Group on Myocardial and Pericardial Diseases. Eur Heart J. 2014;35(34):2279-84. 674. Get With The Guidelines - American Heart Association. [Cited in 2018 Jan 10]. Available from: http://www.heart.org/HEARTORG/Professional/ GetWithTheGuidelines/Get-With-The-Guidelines---HFStroke_ UCM_001099_SubHomePage.jsp. 675. Adesão às Diretrizes Assistenciais de Insuficiência Cardíaca, Fibrilação Atrial e Síndrome Coronariana Aguda: um Programa de Boas Práticas Clínicas emCardiologia. [Citado em 2018 jan 10]. Disponivel em: http:// cardiol.br/boaspraticasclinicas/documentos/protocolo.pdf 676. Ellrodt AG, Fonarow GC, Schwamm LH, Albert N, Bhatt DL, Cannon CP, et al. Synthesizing lessons learned from get with the guidelines: the value of disease-based registries in improving quality and outcomes. Circulation. 2013;128(22):2447-60. 677. Fonarow GC, Abraham WT, Albert NM, Stough WG, Gheorghiade M, Greenberg BH, et al; OPTIMIZE-HF Investigators and Hospitals. Association between performance measures and clinical outcomes for patients hospitalized with heart failure. JAMA. 2007;297(1):61-70. 678. Yancy CW, LopatinM, Stevenson LW, DeMarco T, FonarowGC; ADHERE Scientific Advisory Committee and Investigators. Clinical presentation, management, and in-hospital outcomes of patients admitted with acute decompensated heart failure with preserved systolic function: a report from the AcuteDecompensatedHeart FailureNational Registry (ADHERE) Database. J Am Coll Cardiol. 2006;47(1):76-84. 679. Feltner C, Jones CD, Cené CW, Zheng ZJ, Sueta CA, Coker-Schwimmer EJ, et al. Transitional care interventions to prevent readmissions for persons with heart failure: a systematic reviewandmeta-analysis. Ann InternMed. 2014;160(11):774-84. 680. Bradley EH, Curry L, Horwitz LI, Sipsma H, Wang Y, Walsh MN, et al. Hospital strategies associated with 30-day readmission rates for patients with heart failure. Circ Cardiovasc Qual Outcomes. 2013;6(4):444-50. 681. Albert NM. A systematic review of transitional-care strategies to reduce rehospitalization in patients with heart failure. Heart Lung. 2016;45(2):100-13. 536